Tesamorelin + Ipamorelin (Blend)

Overview

Tesamorelin + Ipamorelin is a dual-peptide blend combining a GHRH analog (Tesamorelin) with a selective ghrelin receptor agonist (Ipamorelin). Similar in concept to the CJC-1295 + Ipamorelin blend, this combination targets two complementary GH release pathways but substitutes the more potent and longer-acting Tesamorelin for CJC-1295.

Mechanism of Action

Tesamorelin provides sustained GHRH receptor stimulation at the pituitary, amplifying the GH synthesis and release signal. Ipamorelin adds ghrelin-mimetic GH release with high selectivity, avoiding cortisol and prolactin elevation. The dual-pathway approach produces a stronger, more physiological GH pulse than either compound alone.

Research Context

This blend is particularly studied for its visceral fat reduction properties, given Tesamorelin's FDA-approved indication in that area. The addition of Ipamorelin may enhance the GH response while maintaining a favorable side-effect profile.

Key Research Areas

Considerations for Researchers

Higher price point reflects the cost of Tesamorelin as a component. Verify blend ratios per vendor. Store lyophilized at -20C. Reconstitute with BAC water.